



aTyr Pharma

aTyr Pharma to Present at Jefferies 2017 Global Healthcare Conference

May 31, 2017

SAN DIEGO, May 31, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the Jefferies 2017 Global Healthcare Conference to be held in New York City from June 6 - 9, 2017.

The aTyr management team will present an overview of the Company during a presentation at 2:00 p.m. ET on Friday, June 9, 2017. The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com. An audio replay will be available for at least 30 days following the initial presentation webcast.

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological pathways. To date, the Company has generated three innovative therapeutic candidate programs based on its knowledge of Physiocrine biology in three different therapeutic areas. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 190 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune imbalance for which there are currently limited or no treatment options. For more information, please visit <http://www.atyrpharma.com>.

Contact:

Mark Johnson

Sr. Director, Investor Relations

mjohnson@atyrpharma.com

858-223-1163

 [Primary Logo](#)

aTyr Pharma Inc.